The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Rini, Brian I., Battle, Dena, Figlin, Robert A., George, Daniel J., Hammers, Hans, Hutson, Tom, Jonasch, Eric, Joseph, Richard W., McDermott, David F., Motzer, Robert J., Pal, Sumanta K., Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924043/
https://www.ncbi.nlm.nih.gov/pubmed/31856918
http://dx.doi.org/10.1186/s40425-019-0813-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924043/
https://www.ncbi.nlm.nih.gov/pubmed/31856918
http://dx.doi.org/10.1186/s40425-019-0813-8

Ejemplares similares